Treatment of B-Cell ALL with Philadelphia Chromosome-Like Features and No BCR::ABL1 Fusion
Clinical Scenario
This protocol addresses B-cell acute lymphoblastic leukemia that carries Philadelphia chromosome-like (Ph-like) genetic features but lacks the BCR::ABL1 fusion gene that characterises classical Ph-positive ALL. About 10–30% of adults with ALL present with this subtype — a molecularly distinct group that differs meaningfully in its response to treatment.
Why This Subtype Requires Special Attention
Ph-like ALL without BCR::ABL1 is notably more resistant to standard chemotherapy than other B-cell ALL subtypes. Its specific genetic profile shapes treatment decisions from the outset, including consideration of consolidation strategies in first remission.
Treatment Approach (Summary)
The approach involves targeted therapies guided by the individual genetic profile of the leukemia — including agents that address specific molecular drivers. Given the resistance characteristics of this subtype, intensification of the overall treatment plan is often considered early.
Full regimen details, sequencing, and decision criteria available in the complete protocol →
References
- About 10 to 30 percent of adults with ALL have a subtype of B-cell ALL with genetic features like Ph+ ALL, but without the BCR::ABL1 fusion gene that defines Ph+ ALL.
- Recent studies have analyzed the genetic profile of patients with some subsets of Ph-like ALL and found that using TKIs and other targeted therapies may help treat these types of leukemia.
- These patients require special attention as Ph-like ALL is more resistant to standard chemotherapy and may require allogeneic transplant in first remission.
View source ↗